162 related articles for article (PubMed ID: 33661013)
1. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809
[TBL] [Abstract][Full Text] [Related]
3. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
Colyn L; Bárcena-Varela M; Álvarez-Sola G; Latasa MU; Uriarte I; Santamaría E; Herranz JM; Santos-Laso A; Arechederra M; Ruiz de Gauna M; Aspichueta P; Canale M; Casadei-Gardini A; Francesconi M; Carotti S; Morini S; Nelson LJ; Iraburu MJ; Chen C; Sangro B; Marin JJG; Martinez-Chantar ML; Banales JM; Arnes-Benito R; Huch M; Patino JM; Dar AA; Nosrati M; Oyarzábal J; Prósper F; Urman J; Cubero FJ; Trautwein C; Berasain C; Fernandez-Barrena MG; Avila MA
Hepatology; 2021 Jun; 73(6):2380-2396. PubMed ID: 33222246
[TBL] [Abstract][Full Text] [Related]
4. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
San José-Enériz E; Agirre X; Rabal O; Vilas-Zornoza A; Sanchez-Arias JA; Miranda E; Ugarte A; Roa S; Paiva B; Estella-Hermoso de Mendoza A; Alvarez RM; Casares N; Segura V; Martín-Subero JI; Ogi FX; Soule P; Santiveri CM; Campos-Olivas R; Castellano G; de Barrena MGF; Rodriguez-Madoz JR; García-Barchino MJ; Lasarte JJ; Avila MA; Martinez-Climent JA; Oyarzabal J; Prosper F
Nat Commun; 2017 May; 8():15424. PubMed ID: 28548080
[TBL] [Abstract][Full Text] [Related]
5. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
6. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.
Bárcena-Varela M; Caruso S; Llerena S; Álvarez-Sola G; Uriarte I; Latasa MU; Urtasun R; Rebouissou S; Alvarez L; Jimenez M; Santamaría E; Rodriguez-Ortigosa C; Mazza G; Rombouts K; San José-Eneriz E; Rabal O; Agirre X; Iraburu M; Santos-Laso A; Banales JM; Zucman-Rossi J; Prósper F; Oyarzabal J; Berasain C; Ávila MA; Fernández-Barrena MG
Hepatology; 2019 Feb; 69(2):587-603. PubMed ID: 30014490
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
8. Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer.
Wang J; Cao Z; Wang F; Wang P; An J; Fu X; Liu T; Li Y; Li Y; Zhao Y; Lin H; He B
Eur J Med Chem; 2021 Dec; 225():113799. PubMed ID: 34500130
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
10. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
Rabal O; Sánchez-Arias JA; San José-Enériz E; Agirre X; de Miguel I; Garate L; Miranda E; Sáez E; Roa S; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2018 Aug; 61(15):6546-6573. PubMed ID: 29890830
[TBL] [Abstract][Full Text] [Related]
11. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
15. G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma.
Hu Y; Zheng Y; Dai M; Wang X; Wu J; Yu B; Zhang H; Cui Y; Kong W; Wu H; Yu X
Cancer Sci; 2019 Nov; 110(11):3442-3452. PubMed ID: 31432592
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
17. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells.
Link PA; Gangisetty O; James SR; Woloszynska-Read A; Tachibana M; Shinkai Y; Karpf AR
Mol Cancer Res; 2009 Jun; 7(6):851-62. PubMed ID: 19531572
[TBL] [Abstract][Full Text] [Related]
18. Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Rahman Z; Bazaz MR; Devabattula G; Khan MA; Godugu C
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22674. PubMed ID: 33283949
[TBL] [Abstract][Full Text] [Related]
19. Current limitations and future opportunities for epigenetic therapies.
Cherblanc F; Chapman-Rothe N; Brown R; Fuchter MJ
Future Med Chem; 2012 Mar; 4(4):425-46. PubMed ID: 22416773
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
